Revvity Sees Steady Growth On Rising Demand From Pharma/Biotech Customers

Revvity Inc. (NYSE:RVTY) on Monday reported fourth quarter 2025 adjusted earnings of $1.70 per share, up 19.7% year over year, beating the consensus of $1.55.

Adjusted operating income was $229 million, as compared to $221 million a year ago.

Adjusted operating profit margin was 29.7% compared to 30.3% a year ago.

The life sciences and diagnostics company reported sales of $772.06 million, up 6% (+4% organic growth), surpassing the consensus of $761.29 million.

“We finished 2025 on a strong note by delivering results that were solidly ahead of our expectations,” said Prahlad Singh, president and CEO of Revvity. “Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come.”

Peers Thermo Fisher Scientific Inc. (NYSE:TMO) and $Danaher Corp(DHR-W)$. (NYSE:DHR) reported better-than-expected earnings.

Life Sciences Segment Snapshot

Fourth quarter Life Sciences revenue was $382 million, up 2% and organic revenue was flat compared to the same period a year ago.

Life Science Diagnostics: Growth from pharma/biotech offset by declines in academic and government demand.

Life Science Solutions: Flat performance despite seasonal improvement, with no year-end budget flush.

Software: Flat results due to renewal timing and tough comps.

Margins: Year-over-year pressure from lower volumes, FX headwinds, and ongoing investments.

Diagnostics Segment Snapshot

Diagnostics revenue increased 10% (+7% organic) to $390 million.

High-single-digit growth in ImmunoDX globally, driven by strength outside China.

Mid-single-digit growth in Reproductive Health, led by strong newborn demand.

Year-over-year margin pressure from tariffs, product mix, and FX impacts.

Guidance

Revvity forecasts fiscal 2026 adjusted earnings of $5.35-$5.45 per share versus the consensus of $5.32. The company expects sales of $2.96 billion-$2.99 billion versus the consensus of $2.93 billion.

The guidance reflects year-over-year growth of 4%-5% and organic growth of 2%-3%.

The company expects an adjusted operating margin of 28%.

RVTY Price Action: Revvity shares were down 4.60% at $103.80 at the time of publication on Monday, according to Benzinga Pro data.

Photo by T. Schneider via Shutterstock